tirzepatide phase 3 trial 80 weeks weight change for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN Tirzepatide after intensive lifestyle intervention

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (under the brand names Ozempic and Rybelsus) and chronic weight management (under the brand name Wegovy)

Retrieved from Toomey, A

LLY, NVO Stocks Led Mays GLP-1 Rally But This Smaller Differentiated Player Got A Bold 160% Upside Call Truist assumed coverage on VKTX with a 'Buy' rating and an $83 price target, implying an upside of 162% from current levels

Find My Treatment KEY BENEFITS Targets both GLP-1 and GIP receptors simultaneously for superior appetite control and fat metabolism

While tirzepatide often shows superior results in trials, its not a one-size-fits-all solution

Helps in stimulating fat burn